BUCHANG PHARMA(SH:603858)2024-04-25 10:51Financial Performance - The company's revenue for Q1 2024 was CNY 2,640,556,945.44, representing a decrease of 24.88% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 114,015,551.69, down 74.96% year-on-year[4] - The basic earnings per share (EPS) was CNY 0.1035, reflecting a decline of 74.86% compared to the previous year[4] - Total operating revenue for Q1 2024 was ¥2,640,556,945.44, a decrease of 24.9% compared to ¥3,514,950,369.96 in Q1 2023[15] - Net profit for Q1 2024 was ¥87,698,871.86, down 80.0% from ¥435,939,044.03 in Q1 2023[15] - The net profit attributable to the parent company's shareholders for Q1 2024 is approximately ¥114 million, a decrease of 75% compared to ¥455 million in Q1 2023[17] - The total comprehensive income attributable to the parent company's shareholders for Q1 2024 is approximately ¥113 million, down from ¥452 million in the same period last year[17] - The basic and diluted earnings per share for Q1 2024 are both ¥0.1035, compared to ¥0.4116 in Q1 2023, reflecting a significant decline[17] Assets and Liabilities - The total assets at the end of the reporting period were CNY 21,306,417,160.89, an increase of 1.98% from the end of the previous year[5] - Total assets as of March 31, 2024, amounted to ¥21,306,417,160.89, an increase from ¥20,892,297,542.28 at the end of 2023[14] - Total liabilities increased to ¥9,986,737,723.37 in Q1 2024 from ¥9,516,288,169.00 in Q4 2023[14] - The total equity attributable to shareholders was ¥11,564,286,419.71 as of March 31, 2024, down from ¥11,616,993,595.29 at the end of 2023[14] Cash Flow - The net cash flow from operating activities was CNY 74,114,961.92, with no applicable comparison due to reporting period specifics[4] - Cash inflows from operating activities for Q1 2024 amount to approximately ¥2.75 billion, a decrease of 19.4% from ¥3.41 billion in Q1 2023[18] - The net cash flow from operating activities for Q1 2024 is approximately ¥74 million, a turnaround from a net outflow of approximately ¥87 million in Q1 2023[18] - The net cash flow from investing activities for Q1 2024 is approximately -¥86 million, compared to -¥318 million in Q1 2023, indicating improved cash management[19] - The net cash flow from financing activities for Q1 2024 is approximately ¥332 million, a significant improvement from a net outflow of approximately -¥134 million in Q1 2023[19] - The cash and cash equivalents at the end of Q1 2024 stand at approximately ¥1.01 billion, down from ¥1.58 billion at the end of Q1 2023[19] - The company received approximately ¥947 million in cash from borrowings during Q1 2024, compared to ¥475 million in Q1 2023, indicating increased leverage[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 71,503[8] - The largest shareholder, Bichang (Hong Kong) Holdings Limited, holds 44.39% of the shares, with 490,957,202 shares pledged[9] Operational Insights - The company reported a significant decrease in sales scale and product sales structure as primary reasons for the profit decline[7] - Research and development expenses increased to ¥46,021,307.86 in Q1 2024, up from ¥36,838,151.85 in Q1 2023[15] - Accounts receivable decreased to ¥1,091,253,325.06 in Q1 2024 from ¥1,567,514,163.15 in Q4 2023[12] - Long-term borrowings rose significantly to ¥2,548,118,637.89 in Q1 2024 from ¥2,097,785,503.89 in Q4 2023[13] - The company reported a decrease in total current liabilities to ¥6,900,970,289.15 in Q1 2024 from ¥6,856,045,867.35 in Q4 2023[13] - The company reported a decrease in cash received from sales of goods and services, totaling approximately ¥2.65 billion in Q1 2024, down from ¥3.31 billion in Q1 2023[18] - Non-recurring gains and losses amounted to CNY 13,160,869.29 for the period[6]